OphtiMed Rx
Novel Molecular Treatment for Dry Age-related Macular Degeneration
StartupOphtiMed Rx is a Afula-based startup in the Health Tech & Life Sciences sector, established in 2021. Novel Molecular Treatment for Dry Age-related Macular Degeneration. The company has raised a total of $1.3M across 1 funding round, currently at the Seed stage. OphtiMed Rx was founded by Dana Rabinovich. Key investors include G.O Innovation. The company has 1-10 employees. Core technologies: Biologicals, Molecules.
With $1.3M in total funding, OphtiMed Rx is a Seed-stage company operating in Health Tech & Life Sciences. The company follows a B2B business model. Product stage: R&D. The company holds 1 patent.
- StageSeed
- ProductR&D
- ModelB2B
- Employees1-10
- HQAfula
- Last Round$1.3M
- G.O InnovationLead
Dana RabinovichCo-founder and CEO
What does OphtiMed Rx do?
OphtiMed Rx is developing a novel molecular therapy for dry age-related macular degeneration (AMD), a common eye disease leading to blindness. The company’s treatment protects retinal cells from senescence (cellular aging) and can halt the progression of dry AMD. OphtiMed Rx’s therapy is designed to prevent the loss of vision and independence caused by dry AMD, providing an enormous benefit to patients.
How much funding has OphtiMed Rx raised?
OphtiMed Rx has raised $1.3M in total funding across 1 rounds. The company is currently at the Seed stage. Key investors include G.O Innovation.
Who founded OphtiMed Rx?
OphtiMed Rx was founded in 2021 by Dana Rabinovich (Co-founder and CEO).
What sector is OphtiMed Rx in?
OphtiMed Rx operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals, Molecules. Target customers: Healthcare & Life Sciences, Healthcare, Laboratories.
Where is OphtiMed Rx located?
OphtiMed Rx is based in Afula, Israel.